Christine Chomienne

Christine Chomienne's AcademicInfluence.com Rankings

Christine Chomienne

Philosophy

#9049

World Rank

#12546

Historical Rank

Logic

#6050

World Rank

#7530

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Christine Chomienne's Degrees

PhD Molecular Biology Université Paris Cité
Masters Biochemistry Université Paris Cité
Bachelors Biology Université Paris Cité

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2025

Why Is Christine Chomienne Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Christine Chomienne's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus (1990) (1387)
The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR (1991) (1373)
All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. (1990) (1257)
Cancer stem cell definitions and terminology: the devil is in the details (2012) (619)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. (2008) (538)
The t(15;17) translocation alters a nuclear body in a retinoic acid‐reversible fashion. (1994) (506)
Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group (1993) (438)
Patterns of somatic structural variation in human cancer genomes (2020) (377)
All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. (1995) (375)
All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. (1990) (368)
Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL (2001) (349)
Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). (1995) (321)
Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia (1998) (280)
Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. (2005) (268)
DNA topoisomerase II in therapy-related acute promyelocytic leukemia. (2005) (261)
PML protein expression in hematopoietic and acute promyelocytic leukemia cells. (1993) (258)
High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. (2006) (239)
Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. (2004) (225)
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists (2013) (223)
Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. (2011) (213)
Physical and Functional Interactions between Cellular Retinoic Acid Binding Protein II and the Retinoic Acid-Dependent Nuclear Complex (1999) (199)
Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. (2004) (194)
Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma (2007) (179)
Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein. (1996) (174)
PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. (1994) (172)
Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. (2006) (168)
Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia (1999) (164)
Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. (1998) (162)
Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? (2007) (162)
Comparison of human skeletal myoblasts and bone marrow-derived CD133+ progenitors for the repair of infarcted myocardium. (2004) (161)
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. (2003) (154)
Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy (2006) (149)
All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. (2001) (147)
Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group (2005) (147)
Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid (1990) (146)
Acute promyelocytic leukemia: biology and treatment. (1997) (143)
Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network (2015) (140)
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome (2010) (138)
CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts (2009) (137)
Retinoid differentiation therapy in promyelocytic leukemia (1996) (136)
Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. (2004) (135)
Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. (1993) (132)
Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. (2005) (131)
RETINOIC ACID THERAPY FOR PROMYELOCYTIC LEUKAEMIA (1989) (128)
Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia (2010) (124)
Clinical and Molecular Characterization of a Rare Syndrome of Acute Promyelocytic Leukemia Associated With Translocation (2002) (123)
Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR (2000) (122)
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial (2000) (121)
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. (2015) (120)
Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. (2009) (119)
Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. (2002) (116)
A PML/retinoic acid receptor alpha fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. (1992) (114)
Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. (2009) (112)
Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. (1992) (109)
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study (2013) (105)
The retinoic acid receptor alpha gene is rearranged in retinoic acid-sensitive promyelocytic leukemias. (1990) (102)
Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms (2008) (102)
Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation (2000) (101)
Juvenile myelomonocytic leukaemia and Noonan syndrome (2014) (99)
Histone Deacetylase Inhibitors (HDI) Cause DNA Damage in Leukemia Cells: A Mechanism for Leukemia-Specific HDI-Dependent Apoptosis? (2006) (99)
Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. (1991) (97)
Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells (2010) (91)
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. (2006) (90)
JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. (2013) (86)
Retinoid acid supports granulocytic but not erythroid differentiation of myeloid progenitors in normal bone marrow cells. (1993) (85)
Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia (1993) (78)
Temporal patterns of bone marrow cell differentiation following transplantation in doxorubicin-induced cardiomyopathy. (2003) (78)
All-trans retinoic acid modulates the retinoic acid receptor-alpha in promyelocytic cells. (1991) (77)
Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience (2003) (74)
PML-RARA–targeted DNA vaccine induces protective immunity in a mouse model of leukemia (2003) (73)
Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia (2010) (71)
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. (2000) (70)
Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial (2003) (70)
In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. (1995) (69)
Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience (2005) (69)
BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. (2007) (67)
Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. (2003) (65)
Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas: Insights for Personalized Therapy (2018) (65)
The Effect of Anti-CD44 Monoclonal Antibodies on Differentiation and Proliferation of Human Acute Myeloid Leukemia Cells (2004) (64)
All trans retinoic acid treatment for patients with acute promyelocytic leukemia. (1992) (63)
Butyric acid and its monosaccharide ester induce apoptosis in the HL-60 cell line. (1993) (62)
Chronic myelomonocytic leukemia: from biology to therapy. (1997) (61)
Lineage-specific modulation of calcium pump expression during myeloid differentiation. (1999) (61)
Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders (2006) (59)
AK2 deficiency compromises the mitochondrial energy metabolism required for differentiation of human neutrophil and lymphoid lineages (2015) (55)
Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. (2013) (54)
Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? (2008) (53)
All-trans retinoic acid in relapsing malignant gliomas: clinical and radiological stabilization associated with the appearance of intratumoral calcifications (1997) (53)
Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukaemia (1994) (50)
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. (2013) (48)
Regulation of the transcriptional activity of nuclear receptors by the MEK/ERK1/2 pathway. (2012) (48)
Cyclin D3 Is a Cofactor of Retinoic Acid Receptors, Modulating Their Activity in the Presence of Cellular Retinoic Acid-binding Protein II* (2003) (46)
Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features (2018) (45)
In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcome. (2001) (42)
Sex differences in oncogenic mutational processes (2019) (41)
Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group. (2012) (39)
CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes ras and junD. (2003) (39)
Variability in the levels of PML-RAR alpha fusion transcripts detected by the laboratories participating in an external quality control program using several reverse transcription polymerase chain reaction protocols. (2001) (39)
Modulation of endoplasmic reticulum calcium pump expression during lung cancer cell differentiation (2013) (39)
Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance (2015) (39)
In vitro all-trans retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. (1994) (39)
Structure-activity relationships of aromatic retinoids on the differentiation of the human histiocytic lymphoma cell line U-937. (1986) (38)
Retroviral transfer and long-term expression of the adrenoleukodystrophy gene in human CD34+ cells. (1998) (37)
All-trans retinoic acid rapidly decreases cathepsin G synthesis and mRNA expression in acute promyelocytic leukemia. (1996) (37)
The epigenetic regulator PLZF represses L1 retrotransposition in germ and progenitor cells (2013) (37)
1 alpha,25-dihydroxyvitamin D3 transrepresses retinoic acid transcriptional activity via vitamin D receptor in myeloid cells. (2004) (37)
Endoplasmic reticulum calcium transport ATPase expression during differentiation of colon cancer and leukaemia cells. (2004) (36)
Biology and treatment of acute promyelocytic leukemia. (1996) (36)
All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study. (1996) (36)
Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera Patients (2010) (36)
1-B-D arabinofuranosyl cytosine and all-trans retinoic acid in combination accelerates and increases monocyte differentiation of myeloid leukemic cells. (1986) (36)
Screening for G-CSF receptor mutations in patients with secondary myeloid or lymphoid transformation of severe congenital neutropenia. A report from the French neutropenia register (2004) (35)
Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group. (1995) (35)
Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia. (1993) (35)
The promyelocytic leukemia zinc finger protein down-regulates apoptosis and expression of the proapoptotic BID protein in lymphocytes (2004) (35)
Modulation of B-cell endoplasmic reticulum calcium homeostasis by Epstein-Barr virus Latent Membrane Protein-1 (2009) (34)
Epigenetic patterns of the retinoic acid receptor β2 promoter in retinoic acid-resistant thyroid cancer cells (2007) (34)
Glucocerebrosidase deficiency dramatically impairs human bone marrow haematopoiesis in an in vitro model of Gaucher disease (2010) (33)
Midkine (MK), a retinoic acid (RA)-inducible gene product, produced in E. coli acts on neuronal and HL60 leukemia cells. (1993) (32)
Long‐term follow‐up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients (2013) (32)
Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. (2007) (32)
Epstein-Barr Virus Latent Membrane Protein 1 Increases Calcium Influx through Store-operated Channels in B Lymphoid Cells* (2011) (31)
Bexarotene via CBP/p300 Induces Suppression of NF-κB–Dependent Cell Growth and Invasion in Thyroid Cancer (2011) (31)
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo (2018) (30)
All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship. (1995) (30)
Preclinical modeling of myelodysplastic syndromes (2017) (30)
Distinct sensitivity of neuroblastoma cells for retinoid receptor agonists: evidence for functional receptor heterodimers (1997) (30)
Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia. (2002) (29)
Selective induction of apoptosis in myeloid leukemic cell lines by monoacetone glucose-3 butyrate. (1994) (29)
The boron-oxygen core of borinate esters is responsible for the store-operated calcium entry potentiation ability (2011) (28)
Bone marrow microenvironment in an in vitro model of Gaucher disease: consequences of glucocerebrosidase deficiency. (2012) (28)
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia (2016) (27)
Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F‐negative polycythaemia vera patients (2008) (27)
Preliminary experience in external quality control of RT-PCR PML-RARα detection in promyelocytic leukemia (1998) (27)
New Role for Granulocyte Colony-Stimulating Factor-Induced Extracellular Signal-Regulated Kinase 1/2 in Histone Modification and Retinoic Acid Receptor α Recruitment to Gene Promoters: Relevance to Acute Promyelocytic Leukemia Cell Differentiation (2011) (26)
Retinoic acids in the treatment of acute promyelocytic leukemia. (1990) (26)
SPOTLIGHT REVIEW Interferon-a therapy in bcr-abl-negative myeloproliferative neoplasms (2008) (26)
Cyclooxygenase-1, but not -2, is upregulated in NB4 leukemic cells and human primary promyelocytic blasts during differentiation (2004) (25)
Complete Hematological, Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon α-2a (peg-IFNα-2a) Therapy in Polycythemia Vera (PV): Long Term Results of a Phase 2 Trial (2011) (24)
Self-renewal gene tracking to identify tumour-initiating cells associated with metastatic potential (2012) (24)
Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent (2015) (24)
DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model. (2010) (24)
A Prospective Study of Bone Marrow Hematopoietic and Mesenchymal Stem Cells in Type 1 Gaucher Disease Patients (2013) (24)
The novel co‐activator CRABPII binds to RARα and RXRα via two nuclear receptor interacting domains and does not require the AF‐2 ‘core’ (2001) (24)
Bone marrow microenvironment in fanconi anemia: a prospective functional study in a cohort of fanconi anemia patients. (2010) (23)
Apoptosis induction by retinoids in eosinophilic leukemia cells: implication of retinoic acid receptor-alpha signaling in all-trans-retinoic acid hypersensitivity. (2006) (23)
Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they? (2013) (22)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
Is AraC Required In the Treatment of Standard Risk APL? Long Term Results of a Randomized Trial (APL 2000) From the French Belgian Swiss APL Group (2010) (21)
In vitro treatment with retinoids or the topoisomerase inhibitor, VP-16, evidences different functional apoptotic pathways in acute promyelocytic leukemic cells. (1995) (21)
Overcoming bacterial DNA contamination in real-time PCR and RT-PCR reactions for LacZ detection in cell therapy monitoring. (2004) (20)
Biological features of primary APL blasts: their relevance to the understanding of granulopoiesis, leukemogenesis and patient management (2001) (20)
Induction of thrombospondin-1 by all-trans retinoic acid modulates growth and differentiation of HL-60 myeloid leukemia cells (1997) (19)
In hematopoietic cells with a germline mutation of CBL, loss of heterozygosity is not a signature of juvenile myelo-monocytic leukemia (2013) (19)
Inefficacy of the synthetic aromatic retinoid etretinate and of its free acid on the in-vitro differentiation of leukemic cells. (1986) (19)
Fanconi's anaemia associated with multicentric Bowen's disease and decreased NK cytotoxicity (1993) (19)
Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO. (2000) (19)
Cooperative action of 1alpha,25-dihydroxyvitamin D3 and retinoic acid in NB4 acute promyelocytic leukemia cell differentiation is transcriptionally controlled. (2005) (18)
Etoposide, an anticancer drug involved in therapy-related secondary leukemia: Enzymes at play (2021) (18)
Identification of JAK2 mutations in canine primary polycythemia. (2011) (18)
Retinoic acid receptor α1 variants, RARα1ΔB and RARα1ΔBC, define a new class of nuclear receptor isoforms (2001) (18)
Induction of retinoid resistance by all-trans retinoic acid in acute promyelocytic leukemia after remission. (1995) (18)
Deregulated expression of promyelocytic leukemia zinc finger protein in B-cell chronic lymphocytic leukemias does not affect cyclin A expression. (2000) (17)
A new variant t(6;15;17)(q25;q22;q21) in acute promyelocytic leukemia: fluorescence in situ hybridization confirmation. (2005) (17)
UV and clean air result in contamination-free PCR (1999) (17)
Telomerase targeting by retinoids in cells from patients with myeloid leukemias of various subtypes, not only APL (2006) (17)
Do Early Events Excluding Patients with Acute Promyelocytic Leukemia (APL) From Trial Enrollment Modify Treatment Result Evaluation? Real-Life Management of 100 Patients Referred to the University Hospital Saint-Louis Between 2000 and 2010. (2010) (16)
Successful xenografts of AML3 samples in immunodeficient NOD/shi-SCID IL2Rγ−/− mice (2012) (16)
Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans (2005) (16)
Changes in the patterns of protein phosphorylation associated with granulocytic and monocytic-induced differentiation of HL-60 cells. (1986) (16)
CD44-ligation induces, through ERK1/2 pathway, synthesis of cytokines TNF-α and IL-6 required for differentiation of THP-1 monoblastic leukemia cells (2010) (16)
Occurrence of myelodysplastic syndrome in 2 patients with reticular dysgenesis. (2011) (15)
An acetyltransferase assay for CREB-binding protein based on reverse phase-ultra-fast liquid chromatography of fluorescent histone H3 peptides. (2015) (15)
Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling (2019) (14)
Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of 18F-FLT PET (2017) (14)
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia (2017) (14)
Simultaneous determination of all-trans and 13-cis retinoic acids and their 4-oxo metabolites by adsorption liquid chromatography after solid-phase extraction. (1995) (14)
CD44 activation enhances acute monoblastic leukemia cell survival via Mcl-1 upregulation. (2012) (14)
Is ARAC Required in the Treatment of Newly Diagnosed APL? Results of a Randomized Trial (APL 2000). (2004) (13)
Effect of 5-aza-2′-deoxycytidine and vitamin D3 analogs on growth and differentiation of human myeloid leukemic cells (1998) (13)
Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis (2018) (13)
The JAK2 46/1 haplotype in splanchnic vein thrombosis. (2011) (13)
Use of the 46/1 haplotype to model JAK2V617F clonal architecture in PV patients: clonal evolution and impact of IFNα treatment (2014) (13)
Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French‐Belgian‐Swiss APL group (2015) (13)
PML–RARα ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL (2010) (13)
Epigenetic Therapy with 5-Azacitidine, Valproic Acid, and ATRA in Patients with High-Risk AML or MDS: Results of the French VIVEDEP Phase II Study (2008) (13)
Type III aminoterminal propeptide of procollagen in some haematological malignancies. (2009) (13)
Potentiation of the store-operated calcium entry (SOCE) induces phytohemagglutinin-activated Jurkat T cell apoptosis. (2015) (12)
When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group). (2009) (12)
Long-Term Outcome in Polycythemia Vera (PV): Final Analysis of a Randomized Trial Comparing Hydroxyurea (HU) to Pipobroman (Pi). (2008) (12)
Treatment of acute promyelocytic leukaemia. (2001) (12)
Differential uptake of all-trans retinoic acid by acute promyelocytic leukemic cells: evidence for its role in retinoic acid efficacy. (1995) (12)
Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study (2000) (12)
PML/RARα rearrangement in acute promyelocytic leukaemia with t(1;17) elucidated using fluorescence in situ hybridization (1997) (12)
Retinoic acid modulates RAR alpha and RAR beta receptors in human glioma cell lines. (1999) (12)
G-CSF activates STAT pathways in Kasumi-1 myeloid leukemic cells with the t(8; 21) translocation: basis for potential therapeutic efficacy. (1997) (12)
Effects of anti-CD 44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines (2001) (12)
Clinical Resistance To Ruxolitinib Is More Frequent In Patients Without MPN-Associated Mutations and Is Rarely Due To Mutations In The JAK2 Kinase Drug-Binding Domain (2013) (11)
Contribution of GM-CSF and IL-8 to the CD44-induced differentiation of acute monoblastic leukemia (2008) (11)
Submicroscopic Insertion of RARα Gene into Chromosome 15 in Two Cases of Acute Promyelocytic Leukemia (2000) (11)
Is the thrombopoietin assay useful for differential diagnosis of thrombocytopenia? Analysis of a cohort of 160 patients with thrombocytopenia and defined platelet life span. (2001) (11)
Frequent antibody production against RARα in both APL mice and patients (2006) (11)
Present results of the treatment of myelodysplastic syndromes with low-dose cytosine arabinoside. Preliminary results of a cooperative protocol (38 patients) and review of the literature. (1987) (11)
Favourable outcome in an APL patient with PLZF/RARalpha fusion gene: quantitative real-time RT-PCR confirms molecular response. (2006) (11)
Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment (2019) (10)
Frequent antibody production against RARalpha in both APL mice and patients. (2006) (10)
Retinoic acid receptor alpha1 variants, RARalpha1DeltaB and RARalpha1DeltaBC, define a new class of nuclear receptor isoforms. (2001) (10)
Risk of leukemic transformation in PV and ET patients. (2004) (10)
Characterization of nuclear retinoic acid binding activity in sensitive leukemic cell lines: cell specific uptake of ATRA and RAR alpha protein modulation. (1995) (10)
GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways (2016) (10)
The novel co-activator CRABPII binds to RARalpha and RXRalpha via two nuclear receptor interacting domains and does not require the AF-2 'core'. (2001) (10)
Flow cytometry comparison of CD34+ subsets in bone marrow and peripheral blood after priming with glycosylated or non-glycosylated rhG-CSF (1999) (10)
Alteration of the PML proto-oncogene in leukemic cells does not abrogate expression of MHC class I antigens (1999) (10)
In vitro all-trans retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. (1994) (10)
Induction treatment of acute promyelocytic leukemia using all-trans retinoic acid. Controversies about dosage, advantages and side-effect management. (1994) (9)
Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses (2020) (9)
Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls (2018) (9)
Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera (2018) (9)
Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission (2020) (9)
Post transcriptional control of the epigenetic stem cell regulator PLZF by sirtuin and HDAC deacetylases (2015) (9)
Retinoic Acid Receptor α (RARα) Mutations in Human Leukemia (2000) (9)
Retinoids and differentiation treatment: a strategy for treatment in cancer. (1994) (9)
Costs of haematological disease high and rising. (2016) (9)
Mapping of the human CD11c (ITGAX) and CD11d (ITGAD) genes demonstrates that they are arranged in tandem separated by no more than 11.5 kb. (1998) (9)
New chimeric RNAs in acute myeloid leukemia (2017) (9)
Quality of Life in hematology: European Hematology Association theme of the year … and years to come (2013) (9)
Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2V617F mutation (2017) (8)
All trans retinoic acid abrogates spontaneous monocytic growth in juvenile chronic myelomonocytic leukaemia. (2001) (8)
Interferon Alpha Therapy Increases Pro-Thrombotic Biomarkers in Patients with Myeloproliferative Neoplasms (2020) (8)
Stimulatory effect of thyroid hormone on RA-induced granulocytic differentiation in leukemic cells. (1991) (7)
Human CREBBP acetyltransferase is impaired by etoposide quinone, an oxidative and leukemogenic metabolite of the anticancer drug etoposide through modification of redox-sensitive zinc-finger cysteine residues. (2020) (7)
The t ( 15 ; 17 ) translocation alters the structure of a nuclear body in a RA-reversible fashion (7)
Remembering John M. Goldman (2014) (7)
A RP-UFLC Assay for Protein Tyrosine Phosphatases: Focus on Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2) (2015) (7)
PHARMACOKINETIC DATA ON VERY-LOW-DOSE CYTARABINE (1986) (7)
Arsenic Trioxide (ATO) In the Consolidation Treatment of Newly Diagnosed APL - First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian Swiss APL Group (2010) (6)
EHA Guidance Document The process of CAR-T cell therapy in Europe. (2019) (6)
Drug association including ara-C in myeloid leukemia cell differentiation: in vitro studies. (1985) (6)
Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes. (2013) (6)
Changes in microrheology of acute promyelocytic leukemia cells during all-trans retinoic acid (ATRA) differentiation therapy: a mechanism for ATRA-induced hyperleukocytosis? (1995) (6)
Low-dose chemotherapy and differentiating agents. (1991) (6)
T-Cell Protein Tyrosine Phosphatase Is Irreversibly Inhibited by Etoposide-Quinone, a Reactive Metabolite of the Chemotherapy Drug Etoposide (2019) (6)
Diagnostic value of bone marrow imaging with 111indium‐transferring and 99mtechnetium‐colloids in myelofibrosis (1985) (6)
Alterations of the retinoic acid receptor α(RARα) gene in myeloid and lymphoid malignancies (1999) (6)
Alterations of the retinoic acid receptor alpha (RAR alpha) gene in myeloid and lymphoid malignancies. (1999) (5)
Prophylactic and therapeutic antileukemic effects induced by the AAC-11-derived Peptide RT53 (2020) (5)
In vitro effects of retinoic acid. (1990) (5)
Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells. (2005) (5)
Lu/BCAM‐mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients (2015) (5)
BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to Treatment (2018) (5)
Tracking the extramedullary PML-RARα-positive cell reservoirs in a preclinical model: biomarker of long-term drug efficacy. (2013) (5)
Sequential Treatment with 5-Azacytidine, Valproic Acid (VPA), and All-Trans Retinoic Acid (ATRA) in Patients with High-Risk Acute Myeloid Leukemia (AML). (2005) (5)
[Mechanism of action of retinoids in a new therapeutic approach to acute promyelocytic leukemia]. (1992) (5)
Age and aging in blood disorders: EHA theme of the year 2013–2014 (2013) (5)
Interaction between mevalonate pathway and retinoic acid-induced differentiation (2001) (5)
PML/RAR alpha rearrangement in acute promyelocytic leukaemia with t(1;17) elucidated using fluorescence in situ hybridization. (1997) (5)
Use of animal models for the treatment of leukemias: Efficacy of DNA vaccination combined with ATRA. (2004) (5)
Granulocytic differentiation induced by retinoic acid in HL-60 cells is associated with changes in adenylate cyclase activity. (1986) (5)
Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN? (2012) (4)
Retinoic acid receptors: involvement in acute promyelocytic leukemia. (1994) (4)
Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare (2022) (4)
Aplastic crisis and erythema infectiosum (fifth disease) revealing a hereditary spherocytosis in a familial human parvovirus infection. (1986) (4)
Autologous111Indium‐oxinate‐labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor‐agonists (2019) (4)
Systematic Evaluation of DNA-Based Quantitative-Polymerase Chain Reaction (Q-PCR) Assays to Track Treatment Response in Patients with JAK2-V617F Associated Myeloproliferative Neoplasms: A Joint European LeukemiaNet/ MPN&MPNr-EuroNet Study (2011) (4)
Future perspectives for acute promyelocytic leukemia therapy. (2001) (4)
DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies (2015) (4)
Metabolic Rewiring Drives Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia (2016) (4)
Retinoids and Differentiation of Normal and Malignant Hematopoietic Cells (1999) (4)
H RAS mutations in haematologically normal individuals. (2000) (4)
Pitfalls in CALR exon 9 mutation detection: A single‐center experience in 571 positive patients (2020) (4)
Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APL– Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group (2013) (4)
Submicroscopic insertion of RARalpha gene into chromosome 15 in two cases of acute promyelocytic leukemia. (2000) (3)
Discrepancy between in vitro and in vivo passaged U-937 human leukemic cells: tumorigenicity and sensitivity to differentiating drugs. (1988) (3)
PLZF Acetylation Levels Regulate NKT Cell Differentiation (2021) (3)
Assessment of PML-RARa Real-Time Quantitative PCR for Definition of Molecular Relapse in APL Patients (Results of the APL Study Group). (2005) (3)
Auer rods and differentiation in acute promyelocytic leukemia (2008) (3)
Feasibility of high-throughput sequencing in clinical routine cancer care: lessons from the cancer pilot project of the France Genomic Medicine 2025 plan (2020) (3)
Which cell type for regeneration of chronically infarcted myocardium ? A face-to-face comparison of skeletal myoblasts and bone marrow-derived hematopoietic stem cells (2003) (3)
Meeting report: the 11th International Conference on Differentiation Therapy and Innovative Therapeutics in Oncology. (2007) (2)
Correction for Cassinat et al., “New Role for Granulocyte Colony-Stimulating Factor-Induced Extracellular Signal-Regulated Kinase 1/2 in Histone Modification and Retinoic Acid Receptor α Recruitment to Gene Promoters: Relevance to Acute Promyelocytic Leukemia Cell Differentiation” (2017) (2)
CD44-Induced differentiation of HL60, NB4, THP1 and KG1a myeloid leukemia cell lines (2000) (2)
All-trans-retinoic acid enhances apoptosis induction by tyrosine kinase inhibitors in the eosinophilic leukemia-derived EoL-1 cell line. (2008) (2)
Revisiting Diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement (2021) (2)
Juvenile chronic myelomonocytic leukemias: molecular and novel therapeutic basis. (1997) (2)
New chimeric RNAs in acute myeloid leukemia. (2017) (2)
Can Peg-Interferon (IFN) α-2a Eradicate JAK2V617F-Positive Bone Marrow Progenitors in Polycythemia Vera (PV)? (2008) (2)
Unexplained thrombocytosis: association of Baltimore polymorphism with germline MPL nonsense mutation (2016) (2)
pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice (2015) (2)
Analysis of JAK2 Mutation in Essential Thrombocythemia (ET) Patients with Monoclonal and Polyclonal X-Chromosome Inactivation Patterns (XCIPs). (2005) (2)
Prognosis scoring system in refractory anemia with excess of blast (RAEB) (1994) (2)
BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome (2021) (2)
Blood disorders stepping into the limelight (2016) (2)
All-trans Retinoic Acid Modulates the Retinoic Acid Receptor-a in Promyelocytic Cells (2003) (2)
Final Results of a Phase 1 Study of 18F-FLT Positron Emission Tomography (PET)/Computed Tomography Imaging in Myelofibrosis (FLT-MF-2009 Study) (2014) (2)
Partial restoration of all trans retinoic acid (ATRA) sensitivity by compactin in ATRA-resistant leukemic cells (ATRA-R HL-60). (2000) (2)
Evaluation of a new thyroglobulin sensitive assay in patients with differentiated thyroid cancer (2015) (2)
NK Cell Mediated Cytotoxicity Against Malignant Promyelocytes Enhanced By Arsenic Trioxide: Potential Clinical Relevance (2013) (2)
Granulocytic colony-stimulating factors (G-CSF and GM-CSF) in the treatment of adult acute myeloid leukemia. (1991) (2)
ABT 737 BCL-2 INHIBITOR TARGETS LEUKEMIC STEM CELLS IN MOUSE MODELS OF MYELOID (PRE)LEUKAEMIA (2009) (2)
Peg IFNα-2a in Polycythemia Vera (PV). Results of a Phase 2 Study by the French “PV-NORD” Group. (2006) (2)
Autologous 111 Indium-Oxinate-Labelled Platelet Sequestration Study in Patients with Immune Thrombocytopenia Treated By Thrombopoietic Receptor-Agonists (2016) (2)
107. The t(15;17) translocation of acute promyelocytic leukemia generates a functionally altered retinoic acid receptor (1992) (1)
Effects of erythropoietin (rHuEpo) plus granulocyte colony stimulating factor (rHuG-CSF) for the treatment of myelodysplastic syndromes (MDS) on anemia, costs and quality of life: a randomized controlled trial. (2004) (1)
BCL-2 Inhibition with ABT-737 Prolongs Survival in an NRAS/BCL2-Mediated MOUSE MODEL of Myelodyspastic Syndrome (MDS) Progressing to ACUTE Myelogenous Leukemia (AML) by Targeting Leukemia Initiating CELLS (2012) (1)
ALL Transretinoic Acid Followed by Intensive Chemotherapy in Newly Diagnosed Acute Promyelocytic Leukemia: A Pilot Study on 27 Cases (1994) (1)
Raising hematology’s European voice: the importance of calling yourself a hematologist (2012) (1)
Genetic instability as an area of potential therapeutic intervention (2007) (1)
Myeloid Leukemia? Repair: A Model for Genomic Instability with Progression in Reactive Oxygen Species, DNA Damage, and Error-Prone (2007) (1)
An analysis of prognostic factors in preleukemia: Interest of bone marrow scintigraphy (1984) (1)
[Current data on GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) in acute myeloid leukemia]. (1992) (1)
Retinoic Acid Receptors (2010) (1)
JAK2V617F - Positive Endothelial Cells Display Pro-Thrombotic Characteristics (2016) (1)
All Trans Retinoic Acid (atRA) Differentiation Markers in Normal and Retinoid-Resistant Acute Promyelocytic Leukemia Cells Revealed Induction of atRA Metabolism as Relevant Prognostic of APL Sensitivity to Therapy. (2005) (1)
A new approach for estimating research impact: An application to French cancer research (2020) (1)
Impact of the Molecular Profile of Malignant Clones on the Response to Interferon Alpha (IFNa) Therapy in JAK2V617F-Negative Essential Thrombocythemia (ET) (2014) (1)
Anemia and hemodilution: analysis of a single center cohort based on 2,858 red cell mass measurements (2020) (1)
Differential expression of c-myc and c-fos oncogenes during the differentiation of human leukemic cells by Ara-C. (1987) (1)
Acute promyelocytic leukemia, the retinoid paradox (1992) (1)
The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3) (2021) (1)
[Cutaneous necrosis of the breast: a complication of oral anticoagulant treatment]. (1983) (1)
15th Congress of European Hematology Association (2010) (1)
[Biological parameters of the efficiency of retinoic acid in acute leukemia]. (1991) (1)
Correction: Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment (2020) (1)
Screening for retinoic acid receptor alpha (RAR alpha) rearrangements in non-APL identifies a novel fusion gene in CMML (1998) (1)
Phase III multicenter randomized trial in RAEB patients of more than 60 years of age: Ara-C 3mg/m2 versus symptomatic treatment (1994) (1)
Proteasome Activity Is Dispensable for the Degradation of PML-RARα: Efficacy of Bortezomib Along with Arsenic Trioxide in the Treatment of Arsenic Sensitive and Resistant Acute Promyelocytic Leukemia (2014) (1)
Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
AK2 Regulates Hematopoietic Cell Survival, Proliferation and Differentiation Along the T-Cell and Neutrophil Lineages (2011) (1)
Resistance to all-trans retinoic acid therapy in acute promyelocytic leukemia: in vitro studies (1994) (1)
Identification of PLZF-Dmrs in Hematopoiesis Highlight a Novel Role of PLZF As a Guardian of Hematopoietic Genome Integrity (2014) (1)
Lack of Association Between the 46/1 JAK2 Haplotype and the Presence of JAK2V617F Mutation In Splanchnic Vein Thrombosis Patients (2010) (1)
Niclas mouse model of AML by targeting primitive LSK and progenitor cells BCL-2 inhibition with ABT-737 prolongs survival in an NRAS / BCL-2 (2013) (1)
TET2 gene sequencing may be helpful for myeloproliferative neoplasm diagnosis (2014) (1)
model of AML by targeting primitive LSK and progenitor cells BCL-2 inhibition with ABT-737 prolongs survival in an NRAS / BCL-2 mouse (2013) (0)
MYELOID NEOPLASIA Clinical and molecular response to interferon- a therapy in essential thrombocythemia patients with CALR mutations (2015) (0)
[Refractory anemia with partial blastosis. A new therapeutic approach]. (1989) (0)
Efficacy of ABT-737, a BCL-2 Inhibitor, in an NRAS/BCL2 Mouse Model of High Risk Myelodysplasia (HR-MDS) By Targeting Pathways Identified By Gene Expression Profiling (2014) (0)
Acquired Resistance to All-Trans Retinoic Acid Therapy in Acute Promyelocytic Leukemia (1996) (0)
[Gene therapy of adrenoleukodystrophy]. (1996) (0)
Clinical Results of All Trans Retinoic Acid (1995) (0)
Epstein-Barr Virus Latent Membrane Protein 1 Increases Calcium Influx through Store-operated Channels in B (2011) (0)
Retinoic acid receptor alpha (RAR alpha) gene rearrangements in non-acute promyelocytic leukaemia (non-APL) [Abstract] (1998) (0)
patients in both APL mice and α Frequent antibody production against RAR (2013) (0)
Biologia Molecolare In vitro effect of retinoic acid and epigenetic modifying drugs on mesenchymal stem cells (2009) (0)
175 ADJUVANT, PVAX14 DNA, AS AN IMMUNOTHERAPY FOR A MOUSE MODEL OF HIGH RISK MYELODYSPLASTIC SYNDROME (HR-MDS) EXTENDS SURVIVAL AS ADD-ON TREATMENT TO AZACITIDINE (AZA) (2015) (0)
Kinetics of indium-oxine labelled red cells in haemolytic anaemias (2004) (0)
Expression and Characterization of Leucocyte Antigens (1984) (0)
Impact of the JAK2V617F Mutation on the Hemato-Endothelial Differentiation in an Induced Pluripotent Stem Cells (iPSC) Model (2014) (0)
in vitro autonomous erythropoiesis of polycythemia vera patient cells Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits (2013) (0)
Autologous Stem Cell Transplantation in Acute Promyelocytic Leukemia Patients Achieving a Second Complete Remission (2000) (0)
Retinoids in normal and leukemic myeloid differentiation (1994) (0)
Combined T reatment W ith A rsenic T rioxide a nd A ll-Trans- Retinoic A cid i n P atients W ith R elapsed A cute Promyelocytic L eukemia (2003) (0)
A novel target for leukemia therapy (2004) (0)
[Towards a personalized pretransplantation conditioning in patients with myelodysplastic syndromes]. (2018) (0)
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
Short tile for running head: tipifarnib in polycythemia vera (2005) (0)
pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid (ATO+ATRA) targeted therapy effectively increases survival of APL mice (2015) (0)
Utilization of hyaluronic acid or fragment thereof for the preparation of a medicament for the regulation of hematopoyeica differentiation. (2000) (0)
Acute promyelocytic leukemia: a model ofpersonalized medicine. (2017) (0)
ANALYSIS OF DRUG‐INDUCED APOPTOSIS BY FLOW CYTOMETRY (1993) (0)
ABT-737 Targets Intrinsic Apoptosis during Cooperation of BCL-2 and Oncogenic NRAS in An in Vivo Progression Model of Myelodysplasia/Acute Myeloid Leukaemia (2008) (0)
Tracking the Extramedullary PML-RARα-Positive Cell Reservoirs in a Preclinical Model of APL: Biomarker of Long-Term Drug Efficacy (2012) (0)
Title Page / Table of Contents, Suppl. 1, 1996 (1996) (0)
Molecular genetics of acute promyelocytic leukemia: the t(15,17) translocation (2009) (0)
Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation (2016) (0)
Mitoxantrone induces DNA topoisomerase II cleavage at translocation breakpoint hotspot in PML gene in acute promyelocytic leukemia (2003) (0)
Lithium Treatment Potentiates Both in Vitro and in Vivo Retinoic Acid Efficacy in APL. (2012) (0)
Mutant BCL2 Co-Operates with CBFβ/PEBP2β-MYH11 to Promote Expansion of Leukemia Initiating Cells with a Predominantly Pro-Apoptotic Mechanism Via Recruitment of Ras-GTP In a Mouse Model of Progressive Acute Myeloid Leukemia. (2010) (0)
NRAS:BCL-2 Complex Localization Determines Anti-Apoptotic Features Associated with Progressive Disease in Myelodysplastic Syndromes (MDS) (2012) (0)
[Retinoic acid: its properties]. (1989) (0)
DNA Vaccination and All-Trans Retinoic Acid Treatment-Induced Long Term Survival Requires CD4+ and CD8+ T-Cell Activation in An APL Mouse Model. (2008) (0)
C035 DNA vaccination as immunotherapy adjuvant in MDS (2009) (0)
ABT-737 Targets Leukemic Stem Cells In Mouse Models of Mutant NRASD12/hBCL-2- Mediated Acute Myeloid Leukemia Progression with Increased Survival (2010) (0)
Diagnosis and outcome prediction for childhood acute leukaemia by gene expression profiling (2004) (0)
retinoic acid sensitivity trans highlights CYP26 cytochrome metabolism in differential all- Pharmacogenomic analysis of acute promyelocytic leukemia cells (2013) (0)
50 BCL2L10-POSITIVE CELL (BPC) QUANTIFICATION IS A PREDICTIVE FACTOR OF SURVIVAL IN AZA-TREATED HIGHER RISK MDS (HR-MDS) AND AML (2015) (0)
Group leukemia. Results of a multicenter randomized trial. European APL 91 Effect of all transretinoic acid in newly diagnosed acute promyelocytic (2013) (0)
S1610 MASKED POLYCYTHEMIA VERA: ANALYSIS OF A SINGLE CENTER SERIES OF 2480 RED CELL MASSES. (2019) (0)
Use of hyaluronic acid or fragments thereof for the manufacture of a medicament for the regulation of hematopoietic differentiation (2000) (0)
VDR-dependent transrepression of retonic acid signaling pathway in 1a,25-dihydroxyvitamin D3-mediated monocytic differentiation. (2002) (0)
9-cis-retinoic acid treatment for myelodysplasia [Abstract] (1998) (0)
Antisense nucleic acid kanamycin for cancer treatment (2010) (0)
[Nuclear receptors and ontogenesis of the hematopoietic tissue]. (1995) (0)
Defining The Translocation Mechanism In Therapy-Related Acute Promyelocytic Leukaemia (2009) (0)
Is There a Role for Red Cell Mass (RCM) Assessment To Classify Myeloproliferative Disorders (MPD) in the JAK2 Era (2007) (0)
Differentiation or Death: The View from Versailles (1998) (0)
Molecular Basis for Retinoic Acid Effects in Acute Promyelocytic Leukemia (1996) (0)
Establishment of Acute myeloid leukemic xenografts as preclinical models of epigenetic therapies (2015) (0)
156 Lenograstim associated or not to ARA-C (3mg/m 2 X2) as therapy for poor prognosis refractory anemia with excess of blasts (RAEB) (1997) (0)
(25 mg/m2) in acute promyelocytic leukemia Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (2011) (0)
Pro-Coagulant and Pro-Inflammatory Effect of Interferon Alpha in Myeloproliferative Neoplasms (2016) (0)
Mutations in the Exon 12 of the JAK2 Gene Appeared To Be a Rare Event Essentially Clustered in V617F JAK2 Negative PV Patients. (2007) (0)
PVN1: A Phase 2 Study of Pegylated Interferon-α2a in Polycythemia Vera (PV) by the “PV-Nord” Group. Preliminary Report of Efficacy and Safety. (2005) (0)
Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases (2010) (0)
Pre-clinical model of acute promyelocytic leukemia: Study of the anti-leukemic effect induced by ATRA and DNA vaccination (2012) (0)
The V617F JAK2 Mutation Is Very Uncommon in Idiopathic Erythrocytosis. (2006) (0)
RAS and BCL-2 co-operate in a mouse model of myelodysplasia (MDS). (2003) (0)
Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
All-Trans Retinoic Acid a s a Differentiation Therapy for Acute Promyelocytic Leukemia (1990) (0)
Comprehensive Analysis of Mesenchymal Cells from Myeloproliferative Neoplasm (MPN) Patients Reveals the Role of HOXB7 in Myelofibrosis Induction (2022) (0)
The H3K36 histone methyltransferase SETD2 as a target of leukemogenic chemicals: molecular and cellular studies. (2018) (0)
DNA and All-Trans Retinoic Acid as Immunotherapy or Add-on Adjuvants to 5-Azacytidine In Myelodysplastic Syndromes (2010) (0)
Post transcriptional control of the epigenetic stem cell regulator PLZF by sirtuin and HDAC deacetylases (2015) (0)
Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
BCL2L10 Quantification Is a Predictive Factor of Response to Azacitidine in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) (2014) (0)
Utilisation de l'acide hyaluronique ou des fragments de celui-ci pour la preparation d'un medicament pour la regulation de la differenciation hematopoietique (2000) (0)
promyelocytic leukemia detected by RNA-based polymerase chain reaction in acute A PML / retinoic acid receptor alpha fusion transcript is constantly (2003) (0)
promyelocytic leukemia. I. Clinical results (see comments) All-trans retinoic acid as a differentiation therapy for acute (2011) (0)
T emporal patterns of bone marrow cell differentiation following transplantation in doxorubicin-induced cardiomyopathy (2003) (0)
In vitro effect of retinoic acid and epigenetic modifying drugs on mesenchymal stem cells (2009) (0)
CD44-Induced Differentiation of Acute Monoblastic Leukemia Cells Is Mediated by Prolonged Activation of ERK1/2 and by Cytokines. (2009) (0)
Uncommon Mutations in PML-RARα Associated with Poor Outcome after First Relapse in APL. (2007) (0)
The V617F JAK2 mutation and the increase in platelet CD36 in essential thrombocythemia are unrelated events (2007) (0)
X-Ray Cristallography Characterization of Human CD44 Epitopes Releasing Differentiation Blockage in Acute Myeloid Leukemia Blasts. (2005) (0)
(MDS) on anemia, costs and quality of life: a randomized controlled trial factor (rHuG-CSF) for the treatment of myelodysplastic syndromes Effects of erythropoietin (rHuEpo) plus granulocyte colony stimulating (2013) (0)
[Treatment of malignant hemopathies with all transretinoic acid]. (1997) (0)
PS1329 IN VIVO 18F-FLUORO-THYMIDINE POSITRON EMISSION TOMOGRAPHY IMAGING FOR DISEASE MONITORING IN A MOUSE MODEL OF HIGH-RISK MYELODYSPLASTIC SYNDROME (2019) (0)
The benzene hematotoxic and reactive metabolite 1,4-benzoquinone impairs the activity of the histone methyltransferase SETD2 and causes aberrant H3K36 trimethylation (H3K36me3) (2021) (0)
Means for the regulation of hematopoietic differentiation (1999) (0)
Human Adenylate Kinase 2 Deficiency Inhibits Hematopoietic Cell Differentiation towards Neutrophil and T Lymphoid Lineages. (2009) (0)
18 F-FLT Positron Emission Tomography (PET)/CT Imaging in Myelofibrosis: A Non Invasive Method to Assess Bone Marrow Function and Extramedullary Hematopoiesis (2012) (0)
Aspirin in Philadelphia-Negative Myeloproliferative Neoplasms: What Is the Optimal Dose ? (2014) (0)
[From Noonan syndrome to juvenile myelomonocytic leukemia]. (2008) (0)
pVAX14 DNA, a Non-Specific DNA Vaccine, Improves Survival In An Acute Promyelocytic Leukemia (APL) Mouse Model Treated With All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO) and Targets Leukemia Initiating Cells (LICs) (2013) (0)
Benzene-Induced Leukemogenesis: Irreversible Inhibition of PTPN2 and Subsequent STAT1 Signaling Alteration By the Hematotoxic Metabolite Benzoquinone (2015) (0)
105. Function of normal and latered retinoic acid binding proteins in acute promyelocytic leukemia (1992) (0)
Yeast Assay Highlights the Intrinsic Genomic Instability of Human PML Intron 6 over Intron 3 and the Role of Replication Fork Proteins (2015) (0)
polycythemia vera through an EpoR-independent Rap1/Akt pathway JAK2V617F activates Lu/BCAM-mediated red cell adhesion in (2014) (0)
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo (2018) (0)
O-14 A reversible two-step model ofMDS/preleukemia: Transgenic mice expressing inducible BCL2 and mutant NRAS (2005) (0)
Register neutropenia: A study of 81 patients from the French Neutropenia Mutations in the ELA2 gene correlate with more severe expression of (2013) (0)
108. PML: a new zinc finger protein involved in the t(15;17) translocation of acute promyelocytic leukemia (1992) (0)
expression of key cancer proteins in acute promyelocytic leukemia Transcriptional repression of microRNA genes by PML-RARA increases (2013) (0)
CD117hi expression identifies a human fetal hematopoietic stem cell population with high proliferation and self-renewal potential (2020) (0)
Comparison of In vivo [18F]Fluoro-desoxyglucose and [18F]Fluoro-thymidine Positron Emission Tomography for Disease Monitoring in a Mouse Model of Higher-Risk Myelodysplastic Syndrome (2021) (0)
CD44-Ligation Triggers IL-1, GM-CSF and IL-8 Driven Differentiation Pathways in Human Monoblastic Leukemia Cells. (2006) (0)
AOP2014/P1101, a Novel Peg-Proline-Interferon Alpha (IFNa) 2b, Specifically Targets JAK2V617F-Positive Polycythemia Vera (PV) Cells (2013) (0)
Engaging European society at the forefront of cancer research and care. (2023) (0)
Increased DNA Damage and Error-Prone Repair in MPD/MDS Mice with Disease Progression: Key Indicators for Increased Genomic Instability. (2004) (0)
myelodysplastic syndromes: a randomized, controlled trial granulocyte colony-stimulating factor for the treatment of Health, economic, and quality-of-life effects of erythropoietin and (2013) (0)
Hematopoietic growth factors. Do they have a role in the management of myelodysplastic syndromes (1997) (0)
Translational Education (2017) (0)
JMML Fetal Identity Results Either from Retention of a Physiologic Signature or Aberrant Activation of Master Oncofetal Regulators (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Christine Chomienne?

Christine Chomienne is affiliated with the following schools:

Christine Chomienne's Academic­Influence.com Rankings